|
Q1 FY2027
As of Jun 30, 2026
|
Q4 FY2026
As of Mar 31, 2026
|
Q3 FY2026
As of Dec 31, 2025
|
Q2 FY2026
As of Sep 30, 2025
|
Q1 FY2026
As of Jun 30, 2025
|
Q4 FY2025
As of Mar 31, 2025
|
Q3 FY2025
As of Dec 31, 2024
|
Q2 FY2025
As of Sep 30, 2024
|
Q1 FY2025
As of Jun 30, 2024
|
Q4 FY2024
As of Mar 31, 2024
|
Q3 FY2024
As of Dec 31, 2023
|
Q2 FY2024
As of Sep 30, 2023
|
Q1 FY2024
As of Jun 30, 2023
|
Q4 FY2023
As of Mar 31, 2023
|
Q3 FY2023
As of Dec 31, 2022
|
Q2 FY2023
As of Sep 30, 2022
|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
Q2 FY2022
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CURRENT ASSETS | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventory [Note 3] | ||||||||||||||||||||
| Deposits and other receivables | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Deposits and other receivables | ||||||||||||||||||||
| Long-term accounts receivable | ||||||||||||||||||||
| Property and equipment [Note 12] | ||||||||||||||||||||
| Operating right of use assets [Note 10] | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| CURRENT LIABILITIES | ||||||||||||||||||||
| Accounts payable and accrued liabilities [Note 4] | ||||||||||||||||||||
| Convertible promissory notes and short term loans [Note 5] | ||||||||||||||||||||
| Term loan, current [Note 6] | ||||||||||||||||||||
| Derivative liabilities [Note 8] | ||||||||||||||||||||
| Advance from customers | ||||||||||||||||||||
| Operating lease obligations, current [Note 10] | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Federally guaranteed loans [Note 7] | ||||||||||||||||||||
| Term loans [Note 6] | ||||||||||||||||||||
| Derivative liabilities [Note 8] | ||||||||||||||||||||
| Operating lease obligations | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| Series B Convertible Redeemable preferred stock, $0.001 and $0.001 par value, 600 and 600 shares authorized as of June 30, 2026 and March 31, 2026, respectively, 335 and 335 shares issued and outstanding as of June 30, 2026 and March 31, 2026, respectively [Note 9] | ||||||||||||||||||||
| Series B Convertible Redeemable Preferred Stock | ||||||||||||||||||||
| Total series B Convertible Redeemable preferred stock, $0.001 and $0.001 par value, 600 and 600 shares authorized as of June 30, 2026 and March 31, 2026, respectively, 335 and 335 shares issued and outstanding as of June 30, 2026 and March 31, 2026, respectively [Note 9] | ||||||||||||||||||||
| STOCKHOLDERS’ (DEFICIENCY) | ||||||||||||||||||||
| Preferred Stock, value | ||||||||||||||||||||
| Preferred Stock | ||||||||||||||||||||
| Preferred Stocks | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Series C Preferred Stock | ||||||||||||||||||||
| Total preferred Stock, value | ||||||||||||||||||||
| Common stock, $0.001 and $0.001 par value, 125,000,000 and 125,000,000 shares authorized as at June 30, 2026 and March 31, 2026, respectively. Issued and outstanding common shares: 20,074,675 and 28,597,315 as at June 30, 2026 and March 31, 2026, respectively, and exchangeable shares of 160,672 and 160,672 outstanding as at June 30, 2026 and March 31, 2026, respectively [Note 9] | ||||||||||||||||||||
| Shares to be issued 581,599 and 1,005,815 shares of common stock as at June 30, 2026 and March 31, 2026, respectively [Note 9] | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ (deficiency) | ||||||||||||||||||||
| TOTAL LIABILITIES, MEZZANINE AND STOCKHOLDERS’ DEFICIENCY | ||||||||||||||||||||
Loading...
